Evidence map›Paper›PMID 38891098›Full record

ReviewCells2024

Photobiomodulation Therapy on Brain: Pioneering an Innovative Approach to Revolutionize Cognitive Dynamics.

Tahsin Nairuz, Sangwoo-Cho, Jong-Ha Lee

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07445945 (Physiological Effect of Non-invasive Photobiomodulation on Cognition and Mood in Older Adults With Subjective Cognitive Impairment), which is not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07445945 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Physiological Effect of Non-invasive Photobiomodulation on Cognition and Mood in Older Adults With Subjective Cognitive Impairment

TypeinterventionalSponsorBaycrestRan2026 to 2028Enrolled80ConditionsSubjective Cognitive Decline (SCD), Subjective Cognitive ImpairmentArmsPhotobiomodulation, Sham (No Treatment)
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Photobiomodulation Increases Eye Movement Conjugation in Healthy Volunteers.Advances in experimental medicine and biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tahsin NairuzDepartment of Biomedical Engineering, Keimyung University, Daegu 42601, Republic of Korea.ORCID 0009-0004-1624-0671
Sangwoo-ChoDepartment of Biomedical Engineering, Keimyung University, Daegu 42601, Republic of Korea.
Jong-Ha LeeDepartment of Biomedical Engineering, Keimyung University, Daegu 42601, Republic of Korea.ORCID 0000-0001-6819-8816

Funding

Basic Research Program through the National Research Foundation of Korea NRF-2022R1I1A307278Digital Innovation Hub project supervised by the Daegu Digital Innovation Promotion Agency (DIP) grant funded by the Korea government (MSIT and Daegu Metropolitan City) in 2023 DBSD1-06Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) HI21C0977, RS-2021-KH118978, RS-2024-00433896Korea Medical Device Development Fund grant funded by the Korea government RS-2022-00166898
6 · The paper itself

Abstract

Photobiomodulation (PBM) therapy on the brain employs red to near-infrared (NIR) light to treat various neurological and psychological disorders. The mechanism involves the activation of cytochrome c oxidase in the mitochondrial respiratory chain, thereby enhancing ATP synthesis. Additionally, light absorption by ion channels triggers the release of calcium ions, instigating the activation of transcription factors and subsequent gene expression. This cascade of events not only augments neuronal metabolic capacity but also orchestrates anti-oxidant, anti-inflammatory, and anti-apoptotic responses, fostering neurogenesis and synaptogenesis. It shows promise for treating conditions like dementia, stroke, brain trauma, Parkinson's disease, and depression, even enhancing cognitive functions in healthy individuals and eliciting growing interest within the medical community. However, delivering sufficient light to the brain through transcranial approaches poses a significant challenge due to its limited penetration into tissue, prompting an exploration of alternative delivery methods such as intracranial and intranasal approaches. This comprehensive review aims to explore the mechanisms through which PBM exerts its effects on the brain and provide a summary of notable preclinical investigations and clinical trials conducted on various brain disorders, highlighting PBM's potential as a therapeutic modality capable of effectively impeding disease progression within the organism-a task often elusive with conventional pharmacological interventions.

Indexed as

BrainCognitionLow-Level Light TherapyAnimalsHumanscognitive functionscytochrome c oxidaseintracranial and intranasal deliveryParkinson’s diseasephotobiomodulation therapystroketranscranial approach

Identifiers

PMID38891098
PMCPMC11171912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.